Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 28;8(8):CD006460.
doi: 10.1002/14651858.CD006460.pub3.

Conventional occlusion versus pharmacologic penalization for amblyopia

Tianjing Li  1 , Riaz Qureshi, Kate Taylor
Affiliations

Conventional occlusion versus pharmacologic penalization for amblyopia

Tianjing Li et al. Cochrane Database Syst Rev. .

Abstract

Background: Amblyopia is defined as impaired visual acuity in one or both eyes without demonstrable abnormality of the visual pathway, and is not immediately resolved by wearing glasses.

Objectives: In performing this systematic review, we aimed to synthesize the best available evidence regarding the effectiveness and safety of conventional occlusion therapy compared to atropine penalization in treating amblyopia.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2018, Issue 8); Ovid MEDLINE; Ovid Embase; LILACS BIREME; ClinicalTrials.gov; ISRCTN; and the WHO ICTRP on 7 September 2018.

Selection criteria: We included randomized/quasi-randomized controlled trials comparing conventional occlusion to atropine penalization for amblyopia.

Data collection and analysis: Two review authors independently screened abstracts and full-text articles, abstracted data, and assessed risk of bias.

Main results: We included seven trials (five randomized controlled trials and two quasi-randomized controlled trials) conducted in six countries (China, India, Iran, Ireland, Spain, and the United States) with a total of 1177 amblyopic eyes. Three of these seven trials were from the original 2009 version of the review. We assessed two trials as having a low risk of bias across all domains, and the remaining five trials as having unclear or high risk of bias for some domains.As different occlusion modalities, atropine penalization regimens, and populations were used across the included trials, we did not conduct any meta-analysis due to clinical and statistical heterogeneity. Evidence from six trials (two at low risk of bias) suggests that atropine penalization is as effective as conventional occlusion in improving visual acuity. Similar improvement in visual acuity was reported at all time points at which it was assessed, ranging from five weeks (improvement of 1 line) to 10 years (improvement of greater than 3 lines). At six months, although most participants (363/522) come from a trial rated as at low risk of bias with a precise estimate (mean difference (MD) 0.03, 95% confidence interval (CI) 0.00 to 0.06), two other trials rated as at high risk of bias produced inconsistent estimates and wide confidence intervals (MD -0.02, 95% CI -0.11 to 0.07 and MD -0.14, 95% CI -0.23 to -0.05; moderate-certainty evidence). At 24 months, additional improvement was found in both groups, but there continued to be no meaningful difference between those receiving occlusion and those receiving atropine therapies (moderate-certainty evidence).We did not find any difference in ocular alignment, stereo acuity, or sound eye visual acuity between occlusion and atropine penalization groups (moderate-certainty evidence). Both treatments were well tolerated. Atropine was associated with better adherence (moderate-certainty evidence) and quality of life (moderate-certainty evidence), but also a higher reported risk of adverse events in terms of mild reduction in the visual acuity of the sound eye not requiring treatment and light sensitivity (high-certainty evidence). Skin, lid, or conjunctival irritation were more common among participants receiving patching than those receiving atropine (high-certainty evidence). Atropine penalization costs less than conventional occlusion.

Authors' conclusions: Both conventional occlusion and atropine penalization produce visual acuity improvement in the amblyopic eye. Atropine penalization appears to be as effective as conventional occlusion, although the magnitude of improvement differed among the trials we analyzed.

PubMed Disclaimer

Conflict of interest statement

Tianjing Li: None known. Riaz Qureshi: None known. Kate Taylor: None known.

Figures

1
1
Study flow diagram.
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Foley‐Nolan 1997 {published data only}
    1. Foley‐Nolan A, McCann A, O'Keefe M. Atropine penalisation versus occlusion as the primary treatment for amblyopia. British Journal of Ophthalmology 1997;81(1):54‐7. - PMC - PubMed
Medghalchi 2011 {published data only}
    1. Medghalchi A, Dalili S. A randomized trial of atropine versus patching for treatment of moderate amblyopia. Iranian Red Crescent Medical Journal 2011;13(8):7‐9. - PMC - PubMed
Menon 2008 {published data only}
    1. Menon V, Shailesh G, Sharma P, Saxena R. Clinical trial of patching versus atropine penalization for the treatment of anisometropic amblyopia in older children. Journal of AAPOS 2008;12(5):493‐7. - PubMed
PEDIG 2002 {published data only}
    1. Hertle RW, Scheiman MM, Beck RW, Chandler DL, Bacal DA, Birch E, et al. Stability of visual acuity improvement following discontinuation of amblyopia treatment in children aged 7 to 12 years. Archives of Ophthalmology 2007;125(5):655‐9. - PMC - PubMed
    1. Holmes JM, Beck RW, Kraker RT, Astle WF, Birch EE, Cole SR, et al. Risk of amblyopia recurrence after cessation of treatment. Journal of AAPOS 2004;8(5):420‐8. - PubMed
    1. Holmes JM, Beck RW, Kraker RT, Cole SR, Repka MX, Birch EE, et al. Impact of patching and atropine treatment on the child and family in the amblyopia treatment study. Archives of Ophthalmology 2003;121(11):1625‐32. - PubMed
    1. Pediatric Eye Disease Investigator Group. A comparison of atropine and patching treatments for moderate amblyopia by patient age, cause of amblyopia, depth of amblyopia, and other factors. Ophthalmology 2003;110(8):1632‐7. - PubMed
    1. Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children. Archives of Ophthalmology 2002;120(3):268‐78. - PubMed
PEDIG 2008 {published data only}
    1. Felius J, Chandler DL, Holmes JM, Chu RH, Cole SR, Hill M, et al. Evaluating the burden of amblyopia treatment from the parent and child's perspective. Journal of AAPOS 2010;14(5):389‐95. - PMC - PubMed
    1. O'Connor MD. Patching vs atropine to treat amblyopia in children aged 7 to 12 years. Evidence‐Based Ophthalmology 2009;10(2):82‐3.
    1. Repka MX, Kraker RT, Beck RW, Birch E, Cotter SA, Holmes JM, et al. Pediatric Eye Disease Investigator Group. Treatment of severe amblyopia with atropine: results from two randomized clinical trials. Journal of AAPOS ‐ 35th Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus, San Francisco, CA United States 2009;13(1):e9.
    1. Repka MX, Kraker RT, Beck RW, Birch E, Cotter SA, Holmes JM, Pediatric Eye Disease Investigator Group. Treatment of severe amblyopia with weekend atropine: results from 2 randomized clinical trials. Journal of AAPOS 2009;13(3):258‐63. - PMC - PubMed
    1. Scheiman MM, Hertle RW, Kraker RT, Beck RW, Birch EE, Felius J, et al. Patching vs atropine to treat amblyopia in children aged 7 to 12 years: a randomized trial. Archives of Ophthalmology 2008;126(12):1634‐42. - PMC - PubMed
Tejedor 2008 {published and unpublished data}
    1. Tejedor J, Ogallar C. Comparative efficacy of penalization methods in moderate to mild amblyopia. American Journal of Ophthalmology 2008;145(3):562‐9. - PubMed
Yan 2008 {published data only}
    1. Yan JJ, Peng HC, Wu CX, Liu ZY, Wang YF. A clinical trial of atropine penalization vs patching for treatment of monocular amblyopia. International Journal of Ophthalmology 2008;8(4):777‐8.

References to studies excluded from this review

Chatzistefanou 2000 {published data only}
    1. Chatzistefanou KI, Mills MD. The role of drug treatment in children with strabismus and amblyopia. Paediatric Drugs 2000;2(2):91‐100. - PubMed
Cole 2001 {published data only}
    1. Cole SR, Beck RW, Moke PS, Celano MP, Drews CD, Repka MX, et al. The Amblyopia Treatment Index. Journal of AAPOS 2001;5(4):250‐4. - PubMed
Huang 2009 {published data only}
    1. Huang Y, Yang J, Zhang D, Shen P. Comparison between blinkers eyeshade occlusion and atropine therapy for the treatment of ametropic amblyopia. International Journal of Ophthalmology 2009;9(8):1615‐7.
Liao 2009 {published data only}
    1. Liao MY, Gao J, He Y. Effect of atropine combined with short‐time occlusion for treating anisometropia amplyopia. International Journal of Ophthalmology 2009;9(7):1394‐5.
PEDIG 2011 {published data only}
    1. Wallace DK, Kraker RT, Beck RW, Cotter SA, Davis PL, Holmes JM, et al. Randomized trial to evaluate combined patching and atropine for residual amblyopia. Archives of Ophthalmology 2011;129(7):960‐2. - PMC - PubMed
    1. Wallace DK, Kraker RT, Davis PL, Holmes JM, Repka MX, Suh DW. A randomized trial to evaluate combined patching and atropine for residual amblyopia. Journal of AAPOS ‐ 36th Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus Orlando, FL United States 2009;14(1):e9.
PEDIG 2013 {published data only}
    1. Wallace DK, Lazar EL, Repka MX, Holmes JM, Kraker RT, Hoover DL, et al. Augmenting atropine treatment for amblyopia in children 3 to < 8 years old (ATS16). Journal of AAPOS 2015;19(1):42‐8.
Scheiman 2005 {published data only}
    1. Scheiman MM, Hertle RW, Beck RW, Edwards AR, Birch E, Cotter SA, et al. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Archives of Ophthalmology 2005;123(4):437‐47. - PubMed
Wu 2006 {published data only}
    1. Wu C, Hunter DG. Amblyopia: diagnostic and therapeutic options. American Journal of Ophthalmology 2006;141(1):175‐84. - PubMed

Additional references

AAO 2012
    1. American Academy of Ophthalmology Pediatric Ophthalmology/Strabismus Panel. Preferred Practice Pattern® Guidelines. Amblyopia. San Francisco, CA: American Academy of Ophthalmology; 2012. www.aao.org/ppp.
Ansons 2001
    1. Ansons A, Davis H. Diagnosis and Management of Ocular Motility Disorders. 3rd Edition. Oxford: Blackwell Science, 2001.
Antonio‐Santos 2014
    1. Antonio‐Santos A, Vedula SS, Hatt SR, Powell C. Occlusion for stimulus deprivation amblyopia. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD005136.pub2] - DOI - PMC - PubMed
AOA 2004
    1. Rouse MW, Cooper JS, Cotter SA, Press LJ, Tannen BM. Care of the patient with amblyopia: reference guide for clinicians. Revised October 1998, reviewed 2004. www.aoa.org/documents/CPG‐4.pdf.
Attebo 1998
    1. Attebo K, Mitchell P, Cumming R, Smith W, Jolly N, Sparkes R. Prevalence and causes of amblyopia in an adult population. Ophthalmology 1998;105(1):154‐9. - PubMed
Brown 2000
    1. Brown SA, Weih LM, Fu CL, Dimitrov P, Taylor HR, McCarty CA. Prevalence of amblyopia and associated refractive errors in an adult population in Victoria, Australia. Ophthalmic Epidemiology 2000;7(4):249‐58. - PubMed
Ciuffreda 1991
    1. Ciuffreda KJ, Levis DM, Selenow A. Amblyopia: Basic and Clinical Aspects. Boston: Butterworth‐Heinemann, 1991.
Covidence 2019 [Computer program]
    1. Veritas Health Innovation. Covidence systematic review software. Version available at: www.covidence.org. Melbourne, Australia: Veritas Health Innovation, 2019.
Deeks 2017
    1. Deeks JJ, Higgins JP, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.
Fells 1990
    1. Fells P. Richardson Cross Lecture 1989 amblyopia — an historical perspective. Eye 1990;4(Pt 6):775‐86. - PubMed
Flom 1985
    1. Flom MC, Bedell HE. Identifying amblyopia using associated conditions, acuity, and nonacuity features. American Journal of Optometry and Physiological Optics 1985;62(3):153‐60. - PubMed
Flynn 1998
    1. Flynn JT, Schiffman J, Feuer W, Corona A. The therapy of amblyopia: an analysis of the results of amblyopia therapy utilizing the pooled data of published studies. Transactions of American Ophthalmological Society 1998;96:431‐50. - PMC - PubMed
Glanville 2006
    1. Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130‐6. - PMC - PubMed
Higgins 2017
    1. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.
Hiscox 1992
    1. Hiscox F, Strong N, Thompson JR, Minshull C, Woodruff G. Occlusion for amblyopia: a comprehensive survey of outcome. Eye 1992;6(3):300‐4. - PubMed
Jones 2003
    1. Jones D, Westall C, Averbeck K, Abdolell M. Visual acuity assessment: a comparison of two tests for measuring children's vision. Ophthalmic and Physiological Optics 2003;23(6):541‐6. - PubMed
Kaye 2002
    1. Kaye SB, Chen SI, Price G, Kaye LC, Noonan C, Tripathi A, et al. Combined optical and atropine penalization for the treatment of strabismic and anisometropic amblyopia. Journal of AAPOS 2002;6(5):289‐93. - PubMed
Levi 2006
    1. Levi DM. Visual processing in amblyopia: human studies. Strabismus 2006;14(1):11‐9. - PubMed
Moseley 2002
    1. Moseley MJ, Neufield M, McCarry B, Charnock A, McNamara R, Rice T, et al. Remediation of refractive amblyopia by optical correction alone. Ophthalmic and Physiological Optics 2002;22(4):296‐9. - PubMed
Newman 1996
    1. Newman DK, Hitchcock A, McCarthy H, Keast‐Butler J, Moore AT. Preschool vision screening: outcome of children referred to the hospital eye service. British Journal of Ophthalmology 1996;80(12):1077‐82. - PMC - PubMed
Newsham 2000
    1. Newsham D. Parental non‐concordance with occlusion therapy. British Journal of Ophthalmology 2000;84(9):957‐62. - PMC - PubMed
PEDIG 2004
    1. Repka MX, Cotter SA, Beck RW, Kraker RT, Birch EE, Everett DF, et al. A randomized trial of atropine regimens for treatment of moderate amblyopia in children. Ophthalmology 2004;111(11):2076‐85. - PubMed
PEDIG 2006
    1. Wallace DK, Edwards AR, Cotter SA, Beck RW, Arnold RW, et al. Pediatric Eye Disease Investigator Group. A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children. Ophthalmology 2006;113(6):904‐12. - PMC - PubMed
PEDSG 2008
    1. Multi‐Ethnic Pediatric Eye Disease Study Group. Prevalence of amblyopia and strabismus in African and Hispanic children ages 6 to 72 months: The Multi‐ethnic Pediatric Eye Disease Study. Ophthalmology 2008;115(7):1229‐36. - PMC - PubMed
PEDSG 2013
    1. Multi‐Ethnic Pediatric Eye Disease Study Group. Prevalence of amblyopia or strabismus in Asian and non‐Hispanic white preschool children: Multi‐ethnic Pediatric Eye Disease Study. Ophthalmology 2013;120(10):2117‐24. - PMC - PubMed
Rahi 2002
    1. Rahi J, Logan S, Timms C, Russell‐Eggitt I, Taylor D. Risks, causes and outcomes of visual impairment after loss of vision in the non‐amblyopic eye: a population based study. Lancet 2002;360(9333):597‐602. - PubMed
Repka 1993
    1. Repka MX, Ray JM. The efficacy of optical and pharmacological penalization. Ophthalmology 1993;100(5):769‐75. - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schünemann 2013
    1. Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.
Simons 1996
    1. Simons K. Preschool vision screening: rationale, methodology and outcome. Survey of Ophthalmology 1996;41(1):3‐30. - PubMed
Simons 1997
    1. Simons K, Stein L, Sener EC, Vitale S, Guyton DL. Full‐time atropine, intermittent atropine, and optical penalization and binocular outcome in treatment of strabismic amblyopia. Ophthalmology 1997;104(12):2145‐55. - PubMed
Simons 1999
    1. Simons K, Preslan M. Natural history of amblyopia owing to lack of compliance. British Journal of Ophthalmology 1999;83(5):582‐7. - PMC - PubMed
Simons 2005
    1. Simons K. Amblyopia characterization, treatment, and prophylaxis. Survey of Ophthalmology 2005;50(2):123‐66. - PubMed
Stewart 2017
    1. Stewart CE, Mosely MJ, Georgiou P, Fielder AR. Occlusion dose monitoring in amblyopia therapy: status, insights, and future directions. Journal of AAPOS 2017;21(5):402‐6. - PubMed
Swann 1974
    1. Swann AP, Hunter CD. A survey of amblyopia treated by atropine occlusion. British Orthoptic Journal 1974;31:65‐9.
Taylor 2012
    1. Taylor K, Powell C, Hatt SR, Stewart C. Interventions for unilateral and bilateral refractive amblyopia. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD005137.pub3] - DOI - PMC - PubMed
Taylor 2014
    1. Taylor K, Elliott S. Interventions for strabismic amblyopia. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD006461.pub3] - DOI - PMC - PubMed
Tommila 1981
    1. Tommila V, Tarkkannen A. Incidence of loss of vision in the healthy eye in amblyopia. British Journal of Ophthalmology 1981;65(8):575‐7. - PMC - PubMed
West 2016
    1. West S, Williams C. Amblyopia in children (aged 7 years or less). BMJ Clinical Evidence 2016;01:0709. - PMC - PubMed
Williams 2002
    1. Williams C, Northstone K, Harrad RA, Sparrow JM, Harvey I, ALSPAC Study Team. Amblyopia treatment outcomes after screening before or at age 3 years: follow up from randomised trial. BMJ 2002;324(7353):1549. - PMC - PubMed
Woodruff 1994
    1. Woodruff F, Hiscox F, Thompson JR, Smith LK. Factors affecting the outcome of children treated for amblyopia. Eye 1994;8(Pt 6):627‐31. - PubMed

References to other published versions of this review

Li 2009
    1. Li T, Shotton K. Conventional occlusion versus pharmacologic penalization for amblyopia. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD006460.pub2] - DOI - PMC - PubMed

Publication types